Abstract
Background & Aims Genome-wide association studies (GWAS) have identified several risk loci for non-alcoholic fatty liver disease (NAFLD). Previous studies have largely relied on small sample sizes and have assessed quantitative traits. We performed a case-control GWAS in the UK Biobank using recorded diagnosis of NAFLD based on diagnostic codes recommended in recent consensus guidelines.
Approach & Results We performed a GWAS of 4,761 cases of NAFLD and 373,227 healthy controls without evidence of NAFLD. Sensitivity analyses were performed excluding other co-existing hepatic pathology, adjusting for BMI and adjusting for alcohol intake. 9,723,654 variants were assessed by logistic regression adjusted for age, sex, genetic principal components and genotyping batch. We performed a GWA meta-analysis using available summary association statistics from two previously published case-control GWAS of NAFLD. Six risk loci were identified (P<5*10^(−8)) of which one is novel in GWAS (rs429358 in APOE) and five are known (PNPLA3, TM6SF2, GCKR, MARC1 and TRIB1). Rs429358 (P=2.17*10^(−11)) is a missense variant within the APOE gene determining ⍰4 vs ⍰2/⍰3 alleles. All loci retained significance in sensitivity analyses without co-existent hepatic pathology and after adjustment for BMI. PNPLA3 and TM6SF2 remained significant after adjustment for alcohol (alcohol intake was known in only 158,388 individuals) with others demonstrating consistent direction and magnitude of effect. All 6 loci were significant on meta-analysis including APOE P=3.42*10^(−13) with consistent direction and magnitude of effect in all 6 loci in all three studies. The ⍰4 allele of APOE offered protection against NAFLD (odds ratio for heterozygotes 0.84 [95%CI 0.78-0.90] and homozygotes 0.64 [0.50-0.79]).
Conclusions This GWAS demonstrates that the ∈4 allele of APOE is strongly associated with protection against NAFLD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by a Medical Research Council Clinical Research Training Fellowship awarded to CJF (MR/T008008/1). Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006] and is currently supported by the Wellcome Trust [216767/Z/19/Z]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award 'STratifying Resilience and Depression Longitudinally' (STRADL) Reference 104036/Z/14/Z). ADB acknowledges funding from the Wellcome PhD training fellowship for clinicians (204979/Z/16/Z), the Edinburgh Clinical Academic Track (ECAT) programme. CH and JFW acknowledges support from the MRC Human Genetics Unit programme grant, 'Quantitative traits in health and disease' (U. MC_UU_00007/10). NCH is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (ref. 219542/Z/19/Z). NLM is supported by the British Heart Foundation through a Senior Clinical Research Fellowship (FS/16/14/32023) and a Research Excellence Award (RE/18/5/34216). RKS is supported by the Wellcome Trust (grant 210752/Z/18/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank received ethical approval (research ethics committee reference 11/NW/0382). Generation Scotland: Scottish Family Health Study received ethical approval (NHS Tayside Research Ethics Committee reference number 05/S1401/89).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* AS and EMH are joint senior authors.
GWAS, genome-wide association study. NAFLD, non-alcoholic fatty liver disease. UK, United Kingdom. BMI, body mass index. APOE, apolipoprotein E. PNPLA3, patatin like phospholipase domain containing 3. TM6SF2, transmembrane 6 superfamily member 2. GCKR, glucokinase regulator. MARC1, mitochondrial amidoxime reducing component 1. TRIB1, tribbles pseudokinase 1. HSD17B13, hydroxysteroid 17-beta dehydrogenase 13. EHR, electronic health record. UKB, UK Biobank. ICD, International Classification of Diseases. GS-SFHS, Generation Scotland: Scottish Family Health Study. SNP, single nucleotide polymorphism. LD, linkage disequilibrium. TC, total cholesterol. STREGA, STrengthening the REporting of Genetic Association Studies.
Financial Support: This work was funded by a Medical Research Council Clinical Research Training Fellowship awarded to CJF (MR/T008008/1). Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006] and is currently supported by the Wellcome Trust [216767/Z/19/Z]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award “STratifying Resilience and Depression Longitudinally” (STRADL) Reference 104036/Z/14/Z). ADB acknowledges funding from the Wellcome PhD training fellowship for clinicians (204979/Z/16/Z), the Edinburgh Clinical Academic Track (ECAT) programme. CH and JFW acknowledges support from the MRC Human Genetics Unit programme grant, “Quantitative traits in health and disease” (U. MC_UU_00007/10). NCH is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (ref. 219542/Z/19/Z). NLM is supported by the British Heart Foundation through a Senior Clinical Research Fellowship (FS/16/14/32023) and a Research Excellence Award (RE/18/5/34216). RKS is supported by the Wellcome Trust (grant 210752/Z/18/Z).
Data Availability
Raw data used in this manuscript is available from the UK Biobank and Generation Scotland. Both studies require an application from a verified researcher.
List of Abbreviations
